How Does Prostate Cancer Metastasize? Studying the Role of Secreted Packages (Exosomes) From Fat Tissue in Lean and Obese Patients (EXOPRO)
The EXOPRO Study: How Does Prostate Cancer Metastasize? Understanding the Role of Exosomal Communication in Lean vs Obese Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Joseph Tam, MBBCh
- Phone Number: +442075942135
- Email: j.tam18@imperial.ac.uk
Study Contact Backup
- Name: Becky Ward
- Phone Number: +442075949459
- Email: becky.ward@imperial.ac.uk
Study Locations
-
-
-
London, United Kingdom, W68RF
- Recruiting
- Charing Cross Hospital, Imperial College Healthcare NHS Trust
-
Contact:
- Joseph Tam, MBBCh
- Phone Number: +442075942135
- Email: j.tam18@imperial.ac.uk
-
Contact:
- Mathias Winkler, FRCS
- Phone Number: +44203311234
- Email: mathias.winkler@nhs.net
-
Principal Investigator:
- Mathias Winkler, FRCS
-
Principal Investigator:
- Joseph Tam, MBBCh
-
Principal Investigator:
- Charlotte Bevan, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All men undergoing radical prostatectomy at Charing Cross Hospital
Exclusion Criteria:
- Patients unable to consent
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Obese patients
BMI > 25
|
Routine NHS Radical Prostatectomy
|
|
Lean patients
BMI < or = 25
|
Routine NHS Radical Prostatectomy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine functional differences of peri-prostatic adipose tissue from lean vs obese patients on prostate cancer cell lines
Time Frame: Through to study completion, on average 3 years
|
Proliferation, migration, invasion, apoptosis and epthelial-mesenchymal transition assays will be performed using isolated exosomes on prostate cancer cell lines
|
Through to study completion, on average 3 years
|
|
Identification of exosomal small RNAs transferred between human adipose tissue to prostate cancer cells lines
Time Frame: Through to study completion, on average 3 years
|
Exosomal RNA transferred from human adipose tissue to prostate cancer cell lines will be isolated using a tagged magnetic bead isolation method and sequenced to identify transferred small RNAs
|
Through to study completion, on average 3 years
|
|
Assess how exosomal small RNAs from lean vs obese patients affect cancer regulation
Time Frame: Through to study completion, on average 3 years
|
Prostate cancer cell lines will be treated with isolated exosomes, then parental and treated cells sequenced to identify differentially expressed RNA and underlying changes
|
Through to study completion, on average 3 years
|
|
Attempt to replicate functional changes observed
Time Frame: Through to study completion, on average 3 years
|
Treatment of prostate cancer cell lines with microRNA mimics or inhibitors and comparison of changes with exosome treated cell lines
|
Through to study completion, on average 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Charlotte Bevan, PhD, Imperial College London
- Principal Investigator: Mathias Winkler, FRCS, Imperial College Healthcare NHS Trust
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 19HH5065
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.